Naloxegol
CAS: 854601-70-0
Ref. 3D-FN157377
| 1mg | Discontinued | ||
| 2mg | Discontinued | ||
| 5mg | Discontinued | ||
| 10mg | Discontinued | ||
| 25mg | Discontinued |
Product Information
- MovantikNKTR 118
- (5α,6α)-4,5-Epoxy-6-(3,6,9,12,15,18,21-heptaoxadocos-1-yloxy)-17-(2-propen-1-yl)morphinan-3,14-diol
- Morphinan-3,14-diol, 4,5-epoxy-6-(3,6,9,12,15,18,21-heptaoxadocos-1-yloxy)-17-(2-propen-1-yl)-, (5α,6α)-
- NKTR 118
- Morphinan-3,14-diol, 4,5-epoxy-6-(3,6,9,12,15,18,21-heptaoxadocos-1-yloxy)-17-(2-propenyl)-, (5α,6α)-
Naloxegol is an opioid that has been approved by the FDA for the treatment of chronic constipation in adults with irritable bowel syndrome (IBS) and opioid-induced constipation. It is also used to treat opioid-induced constipation in patients with chronic noncancer pain. Naloxegol is a peripherally selective μ-opioid receptor antagonist that blocks the binding of endogenous opioids, such as endorphins, enkephalins, and dynorphins, to the μ-receptor on nerve cells in the gastrointestinal tract. Naloxegol has been shown to be effective in improving symptoms of constipation in IBS patients with or without concurrent abdominal pain. The drug does not affect normal bowel function, nor does it cause dependence or addiction. Naloxegol is not effective for treating diarrhea-predominant IBS patients.
